24/7 Market News Snapshot 23 July, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

July 23, 2025

DENVER, Colo., 23 July, 2025 (www.247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
Plus Therapeutics, Inc. (PSTV) is experiencing an upward trajectory in its stock performance, opening at $0.436 and currently trading at $0.508, marking a significant increase of 19.53%. This surge follows a previous close of $0.425, indicating heightened investor interest. The trading volume has reached 9.22 million shares, reflecting robust market activity and suggesting a bullish sentiment among investors. Notably, the stock’s recent breakout above a previous resistance level may signal potential for further gains. Investors are advised to keep an eye on continued volume support and possible pullbacks that may present additional buying opportunities for this dynamic biotech entity.

In a promising development, Plus Therapeutics has secured an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of an awarded grant totaling $17.6 million. This financial infusion supports the company’s focus on developing advanced targeted radiotherapeutics for central nervous system (CNS) cancers. Andrew Sims, Chief Financial Officer of Plus Therapeutics, expressed optimism regarding the funding, highlighting that it, along with an anticipated additional $6 million in the coming year, offers essential non-dilutive financing for their clinical initiatives.

The funding will be instrumental in advancing the clinical development of REYOBIQ™ (rhenium Re186 obisbemeda) through the ReSPECT-LM dose optimization trial. This innovative injectable radiotherapy is designed to deliver potent radiation directly to CNS tumors, aiming to improve patient outcomes while reducing adverse effects. Given the limited treatment options for leptomeningeal metastases, Plus Therapeutics is addressing a critical need by focusing on solutions for recurrent glioblastoma and pediatric brain cancer.

As the company continues to explore additional funding avenues and expand its clinical programs, it is committed to enhancing treatment alternatives for patients confronted with some of the most challenging cancers.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.